Faron Pharma Share News (FARN)

Faron Pharma celebrates positive read-out in ongoing MDS trial

(Alliance News) - Faron Pharmaceuticals Ltd on Monday noted a positive read-out regarding the ongoing Bexmab trial on myelodysplastic syndrome, a form of cancer.

TRADING UPDATES: Kelso raises stake in NCC; Transense joins project

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and Tuesday and not separately reported by Alliance News:

Faron Pharmaceuticals extends funding agreement with IPF

(Sharecast News) - Faron Pharmaceuticals announced on Tuesday that it has extended its agreement with lender IPF to ensure continued financial support as it progressed towards securing longer-term funding.

Faron Pharmaceuticals reappoints former finance chief on interim basis

(Alliance News) - Faron Pharmaceuticals Ltd on Monday said it appointed a new interim chief financial officer to replace the outgoing James O'Brien.

Faron Pharmaceuticals CFO stands down

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals revealed on Monday that chief financial officer James O'Brien would be leaving the group to "pursue another career opportunity".

UPDATE: Faron Pharmaceuticals promotes COO to CEO as father retires

(Alliance News) - Faron Pharmaceuticals Ltd on Monday said it will promote its chief operating officer to chief executive to replace his father, the company's founder.

Faron Pharmaceuticals promotes COO to CEO as founder steps back

(Alliance News) - Faron Pharmaceuticals Ltd on Monday said it will promote its chief operating officer to chief executive to replace the company's founder.

Faron Pharmaceuticals taps Juho Jalkanen for CEO

(Sharecast News) - Biopharmaceutical company Faron Pharmaceuticals named Dr Juho Jalkanen as its next chief executive officer on Monday.

Faron Pharmaceuticals secures funding to deliver next "milestones"

(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said it has successfully raised funds to support the phase two study of its bexmarilimab cancer treatment.

TRADING UPDATES: Quiz sales fall, names new CEO; Byotrol eyes AIM exit

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

UK shareholder meetings calendar - next 7 days

LONDON MARKET CLOSE: Stocks downbeat before central bank rate storm

(Alliance News) - Stocks in London closed in the red on Monday, as tech gains in New York failed to make an impact ahead of several interest rate decisions from central banks across the world this week.

Faron shares jump on encouraging trial data

(Sharecast News) - Faron Pharmaceuticals announced further encouraging data from the first phase of its 'BEXMAB' trial on Monday, targeting higher-risk (HR) myelodysplastic syndrome (MDS) patients who had failed prior hypomethylating agent (HMA) treatment.

Faron Pharmaceuticals shares jump on positive data from Bexmab study

(Alliance News) - Faron Pharmaceuticals Ltd on Monday said a study showed more patients responding to treatment in a new readout of the Bexmab study focused on myelodysplastic syndrome, or MDS.

AIM WINNERS & LOSERS: Clontarf raises GBP400,000; Faron jumps

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.